Go Deep
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 9,344 | 85.8 | 32.97 | 0.06 | 66.94 |
| Oct 2026 | 7,093 | 85.2 | 32.74 | 0.06 | 66.47 |
Shukra Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 235,223,000.0 | 63,241,000.0 | 391,348,000.0 | 58,774,000.0 |
| Net Profit | 129,585,000.0 | -17,162,000.0 | 203,646,000.0 | 23,781,000.0 |
| EPS | 0.3 | -0.0 | 0.5 | 0.1 |
Shukra Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 567,274,000.0 | 325,873,000.0 | 745,729,000.0 | 588,336,000.0 | — |
| Net Profit | 220,584,000.0 | 95,751,000.0 | 185,372,000.0 | 44,065,000.0 | — |
| EPS | 0.5 | 0.2 | 0.4 | 0.1 | — |
Shukra Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 1,174,400,000.0 | 867,698,000.0 | 778,371,000.0 | 749,664,000.0 | — |
| Total Liabilities | 275,910,000.0 | 239,341,000.0 | 202,028,000.0 | 496,697,000.0 | — |
| Total Equity | 898,490,000.0 | 628,357,000.0 | 576,343,000.0 | 252,967,000.0 | — |
Owes vs Owns
Shukra Pharmaceuticals Limited owed ₹0.23 for every ₹1 it owned in Mar 2026, down from ₹0.66 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.23× | 0.28× | 0.26× | 0.66× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Shukra Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 5.1%Receivables 19.5%Inventory 11.8%Fixed assets (tangible) 28.6%Other assets 34.9%
How it's funded — Mar 2026
Short-term debt 1.6%Long-term debt 2.7%Payables 8.6%Other liabilities 10.6%Shareholders' equity 76.5%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 6.0 | 12.1 | 10.0 | 4.0 |
| Receivables | 22.9 | 8.8 | 24.5 | 30.2 |
| Inventory | 13.9 | 10.0 | 2.3 | 3.2 |
| Fixed assets (tangible) | 33.6 | 21.3 | 21.6 | 21.9 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 41.0 | 34.6 | 19.4 | 15.8 |
| Liabilities & equity | ||||
| Short-term debt | 1.8 | 1.1 | 0.5 | 1.3 |
| Long-term debt | 3.2 | 3.1 | 2.7 | 3.8 |
| Payables | 10.1 | 9.2 | 7.2 | 33.6 |
| Other liabilities | 12.5 | 10.5 | 9.8 | 11.0 |
| Shareholders' equity | 89.8 | 62.8 | 57.6 | 25.3 |
| Net tangible assets | 89.8 | 62.8 | 57.6 | 25.3 |
Shukra Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 39,313,000.0 | 79,184,000.0 | -51,968,000.0 | 31,695,000.0 | — |
| Investing Activities | -141,431,000.0 | -12,636,000.0 | -12,009,000.0 | -44,271,000.0 | — |
| Financing Activities | 40,703,000.0 | -45,175,000.0 | 124,050,000.0 | 49,411,000.0 | — |